Actively Recruiting
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-03-26
1384
Participants Needed
8
Research Sites
313 weeks
Total Duration
On this page
Sponsors
C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead Sponsor
P
Peking Union Medical College Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn about whether it is safe to omit dissection of the No.253 lymph nodes in mid and low rectal cancer surgery. The main question it aims to answer is that if it is possible to achieve the same long-term survival with and without the dissection of the No.253 lymph node in mid and low rectal cancer surgery. Participants will underwent laparoscopic rectal radical resection with or without the dissection of the No.253 lymph node.
CONDITIONS
Official Title
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Colon biopsy confirms adenocarcinoma
- Tumor lower edge is 7 cm or less from the anus by colonoscopy and imaging
- Tumor T stage is 3 or less by imaging
- No enlarged lymph nodes at the root of the inferior mesenteric artery by imaging
- Three or fewer mesenteric metastatic lymph nodes by imaging
- Strong willingness to undergo surgery and signed informed consent
You will not qualify if you...
- Previous malignant colorectal tumors
- Biopsy shows mucinous adenocarcinoma or signet ring cell carcinoma
- Distant metastasis diagnosed by imaging
- History of multiple abdominal-pelvic surgeries or extensive abdominal adhesions
- Complications requiring emergency surgery such as intestinal obstruction, perforation, or bleeding
- Extensive lesions not suitable for complete tumor removal (R0 resection)
- Other malignancies diagnosed within the past five years
- ASA class IV or higher and/or ECOG performance score 2 or higher
- Severe liver, kidney, heart, lung, coagulation dysfunctions, or serious underlying diseases preventing surgery
- History of severe mental illness
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
2
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029
Not Yet Recruiting
3
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Not Yet Recruiting
4
Chinese PLA General Hospital
Beijing, Beijng, China, 100141
Not Yet Recruiting
5
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Chaoyang District, China, 100021
Actively Recruiting
6
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Not Yet Recruiting
7
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
8
West China Hospital Sichuan University
Chengdu, Sichuan, China, 610044
Not Yet Recruiting
Research Team
M
Mingguang Zhang, Dr.
CONTACT
Q
Qian Liu, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here